尿失禁治療藥物市場：按失禁類型、按藥物類別、按配銷通路、按地區

預計2023年全球尿失禁藥物市場規模為44.1億美元，預測期間（2023-2030年）年複合成長率為3.4%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	44.1億美元
實績資料	2018-2021	預測期	2023-2030
預測期年複合成長率	3.40%	2030年市場規模預測	55.6億美元

圖 1. 2023 年尿失禁藥物的全球市場佔有率（按失禁類型）

尿失禁意味著膀胱失控且不自主地漏尿。在這種情況下，尿道括約肌的控制減弱或完全喪失，導致患者排尿時沒有排尿的衝動。這是一個非常常見且常常令人尷尬的問題。排尿時，尿道周圍的肌肉放鬆，尿液被排放體外，但尿失禁時，尿道周圍的肌肉無法正常運作，導致尿液漏出。尿失禁可能是由日常生活習慣、潛在疾病或身體問題引起的。尿失禁有多種類型，包括壓力性尿失禁（膀胱壓力）、尿急性尿失禁（強烈排尿慾望）和溢尿性尿失禁（慢性閉尿症）。尿失禁的嚴重程度取決於健康狀況，如尿道感染(UTI)、便秘和尿失禁。尿失禁在老年族群中較常見。

市場動態

新興市場的主要參與者正在專注於開發具有成本效益的解決方案。因此，市場上新的先進產品的推出預計將在預測期內推動全球尿失禁藥物市場的成長。例如，2023年3月15日，大型製藥公司MSN Laboratories宣布推出全球首個生物等效仿製富馬酸非索羅定藥物Fesobig。 Fesobig被多項國際治療指南推薦為治療膀胱過動症（OAB）和尿失禁（UI）最安全、新穎的第一線藥物。該公司正在確保這種藥物價格實惠，以便使許多患者受益。膀胱過動症（OAB）是一種由骨盆底功能障礙引起的非自願性尿失禁，多見於女性。印度尿失禁的盛行率也較高，農村地區為10%，都市區為34%。雖然尿失禁不會危及生命，但它會導致不適、羞恥和喪失自信。

本研究的主要特點

• 本報告對全球尿失禁治療市場進行了詳細分析，並列出了以2022年為基準年的預測期（2023-2030年）的市場規模和復合年度（年複合成長率）。
• 它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
• 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
• 它根據公司亮點、產品系列、主要亮點、業績和策略等參數，介紹了全球尿失禁治療藥物市場的主要企業。
• 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
• 全球尿失禁治療藥物市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
• 透過用於分析全球尿失禁治療藥物市場的各種策略矩陣，將有助於相關人員做出決策。

目錄

第1章 調查目的和假設

• 這項研究的目的
• 假設
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章 市場動態、法規及趨勢分析

• 市場動態
  • 促進因素
  • 抑制因素
  • 市場機會
• 最近的趨勢
• 最近推出/核准
• 合併、收購和合作
• 法規場景
• 主要進展
• PEST分析
• 波特的分析

第4章 全球尿失禁治療藥物市場 - COVID-19 的影響分析

• 經濟影響
• 新型冠狀病毒感染疾病（COVID-19）的流行病學
• 對需求和供給的影響

第5章 2018-2030年全球尿失禁治療藥物市場（按失禁類型）

• 急迫性尿失禁
• 應力性尿失禁
• 溢流性尿失禁
• 混合性失禁
• 其他類型的失禁

第6章 全球尿失禁治療藥物市場，依藥物類別，2018-2030

• 抗膽鹼能/解痙
• 骨骼肌鬆弛劑
• 抗憂鬱症
• α阻斷劑
• 局部雌激素
• 其他

第7章 全球尿失禁治療藥物市場，依配銷通路，2018-2030

• 醫院藥房
• 零售藥房
• 網路藥房

第8章 2018-2030年全球尿失禁治療藥物市場（按地區）

• 北美洲
• 美國
• 加拿大
• 歐洲
• 英國
• 德國
• 義大利
• 法國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 中國
• 印度
• 日本
• ASEAN
• 澳洲
• 韓國
• 其他亞太地區
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲
• 中東
• GCC
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中部非洲
• 南非

第9章 競爭形勢

• 公司簡介
  • Johnson &Johnson
  • Pfizer Inc.
  • Astellas Pharma, Inc.
  • Allergan, Inc.
  • Takeda Pharmaceutical Company Limited
  • Merck &Co., Inc.
  • Sanofi SA
  • IXALTIS
  • Bayer AG
  • elicept Therapeutics
  • Taiho Pharmaceutical
  • Cook MyoSite
  • Urovant Sciences GmbH
  • Analysts'Views

第10章 章

• 參考
• 調查方法

Global Urinary Incontinence Treatment Drugs Market is estimated to be valued at US$ 4.41 Bn in 2023, and is expected to exhibit a CAGR of 3.4% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 4.41 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	3.40%	2030 Value Projection:	US$ 5.56 Bn

Figure 1. Global Urinary Incontinence Treatment Drugs Market Share (%), By Incontinence Type, 2023

Urinary incontinence means losing control of bladder that leads to involuntary leakage of urine. In this condition, control over the urinary sphincter is weakened or completely lost, and thus, a person urinates even when they do not want to. This is a very common and often embarrassing problem for people. At the time of urination, muscles around urethra relax and let urine pass out of the body, however, in urinary incontinence, muscles around urethra do not work in the way they should, and resulting in leak of urine. Urinary incontinence can be caused by everyday habits, underlying medical conditions, or physical problems. There are various type of incontinences such as stress (bladder is under pressure), urge (intense urge to pass urine), and overflow (chronic urinary retention). The severity of urinary incontinence varies as per the health conditions such as urinary tract infection (UTI), constipation, and urinary incontinence . Urinary incontinence is found more in geriatric population.

Market Dynamics

Key players in the market are focusing on the development of cost efficient solutions. Thus, introduction of new and advanced products in the market is expected to drive growth of the global urinary incontinence treatment drugs market over the forecast period. For instance, on March 15, 2023, MSN Laboratories, a leading pharmaceutical company, announced the launch of Fesobig, the world's first bioequivalent generic version of fesoterodine fumarate. Fesobig is recommended by various international treatment guidelines for the treatment of overactive bladder (OAB) and urinary incontinence (UI), as the safest and novel first-line pharmacotherapy option. The company have ensured that the drug has an affordable price so that it can benefit a large majority of patients. As overactive bladder (OAB) is an involuntary loss of urine due to pelvic floor dysfunction, which is strongly associated with the female population. The prevalence of urinary incontinence in India is also relatively high, ranging from 10% in rural areas to 34% in urban areas. Although urinary incontinence is not a life-threatening condition, it causes discomfort, embarrassment and a loss of self-confidence.

Key features of the study:

• This report provides an in-depth analysis of the global urinary incontinence treatment drugs market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global urinary incontinence treatment drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Sanofi S.A., IXALTIS, Bayer AG, elicept Therapeutics, Taiho Pharmaceutical, Cook MyoSite and Urovant Sciences GmbH
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global urinary incontinence treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urinary incontinence treatment drugs market

Global Urinary Incontinence Treatment Drugs Market Detailed Segmentation:

• By Incontinence Type:
  • Urge Incontinence
  • Stress Incontinence
  • Over-flow Incontinence
  • Mixed Incontinence
  • Other Incontinence Type
• By Drug Class:
  • Anticholinergic/Antispasmodic Agents
  • Skeletal Muscle Relaxants
  • Antidepressants
  • Alpha Blockers
  • Topical Estrogens
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Company Profiles
  • Johnson & Johnson
  • Pfizer Inc.
  • Astellas Pharma, Inc.
  • Allergan, Inc.
  • Takeda Pharmaceutical Company Limited
  • Merck & Co., Inc.
  • Sanofi S.A.
  • IXALTIS
  • Bayer AG
  • elicept Therapeutics
  • Taiho Pharmaceutical
  • Cook MyoSite
  • Urovant Sciences GmbH

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Incontinence Type
  • Market Snippet, By Drug Class
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Recent Trends
• Recent Launches/Approvals
• Mergers, Acquisitions, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis
• PORTER's Analysis

4. Global Urinary Incontinence Treatment Drugs Market - COVID-19 Impact Analysis

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Urinary Incontinence Treatment Drugs Market, By Incontinence Type, 2018- 2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Urge Incontinence
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends
• Stress Incontinence
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends
• Over-flow Incontinence
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends
• Mixed Incontinence
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends
• Other Incontinence Type
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends

6. Global Urinary Incontinence Treatment Drugs Market, By Drug Class, 2018 - 2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Anticholinergic/Antispasmodic Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends
• Skeletal Muscle Relaxants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends
• Antidepressants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends
• Alpha Blockers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends
• Topical Estrogens
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends

7. Global Urinary Incontinence Treatment Drugs Market, By Distribution Channel, 2018 - 2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

8. Global Urinary Incontinence Treatment Drugs Market, By Region, 2018 - 2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Incontinence Type, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
• U.S.
• Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Incontinence Type, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Incontinence Type, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Incontinence Type, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Incontinence Type, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Incontinence Type, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 -2030, (US$ Bn)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Company Profiles
  • Johnson & Johnson
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Pfizer Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Astellas Pharma, Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Allergan, Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Takeda Pharmaceutical Company Limited
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Merck & Co., Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Sanofi S.A.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • IXALTIS
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Bayer AG
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • elicept Therapeutics
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Taiho Pharmaceutical
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Cook MyoSite
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Urovant Sciences GmbH
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Analysts' Views

10. Section

• References
• Research Methodology
• About us and Sales Contact